TO WHOM AND WHAT TO PRESCRIBE, HOW LONG TO TREAT


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Osteoporosis is a common disease of the skeleton. Treatment of osteoporosis is aimed at reducing the risk of fractures that occur against a background of reduced mineral density and changes in microarhitectonicsc of bone tissue. Currently, there are several anti-osteoporotic drugs that are used throughout the world in the arsenal of doctors, among them bisphosphonates, denosumab, teriparatide and strontium ranelate. The article discusses the issues of choice of drug therapy and the tactics of management of patient with osteoporosis.

Texto integral

Acesso é fechado

Sobre autores

Oksana NIKITINSKAYA

Email: nikitinskayaox@yandex.ru
PhD, senior researcher of the Laboratory of osteoporosis, V.A. Nasonova Research Institute of Rheumatology. 115522, Moscow, 34A Kashirskoe shosse

Nataliya TOROPTSOVA

Email: torop@irramn.ru
D, head of the Laboratory of osteoporosis, V.A. Nasonova Research Institute of Rheumatology. 115522, Moscow, 34A Kashirskoe shosse

Bibliografia

  1. Михайлов Е.Е., Беневоленская Л.И. Руководство по остеопорозу. Под ред. Л.И. Беневоленской. М.: БИНОМ. Лаборатория знаний, 2003:10-53. [Mikhailov Ye.Ye., Benevolenskaya L.I. Guidelines for osteoporosis. Under the editorship of L.I. Benevolenskaya. Moscow: BINOM. Laboratory of knowledge, 2003:10-53 (in Russ.)]
  2. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017. 464 с. [Russian clinical recommendations. Rheumatology. Under the editorship of Ye.L. Nasonov. Moscow: GEOTAR-Media, 2017. 464 p. (in Russ.)]
  3. Diez-Perez A., Adachi J.D., Agnusdei D., Bilezikian J.P., Compston J.E., Cummings S.R., Eastell R., Eriksen E.F., Gonzalez-Macias J., Liberman U.A., Wahl D.A., Seeman E., Kanis J.A., Cooper C.; IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos. Int. 2012;23(12):2769-74.
  4. Silverman S.L., Adachi J.D., Dennison E.; International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Bisphosphonate drug holidays: we reap what we sow. Osteoporos. Int. 2016;27(3):849-52.
  5. Adler R.A., El-Hajj Fuleihan G., Bauer D.C., Camacho P.M, Clarke B.L., Clines G.A., Compston J.E., Drake M.T., Edwards B.J., Favus M.J., Greenspan S.L., McKinney R. Jr, Pignolo R.J., Sellmeyer D.E. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2016;31(1):16-35.
  6. Compston J., Cooper A., Cooper C., Gittoes N., Gregson C., Harvey N., Hope S., Kanis J.A., McCloskey E.V., Poole K.E.S., Reid D.M., Selby P., Thompson F., Thurston A., Vine N.; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch. Osteoporos. 2017;12:43.
  7. McNabb B.L., Vittinghoff E., Schwartz A.V., Eastell R., Bauer D.C., Ensrud K., Rosenberg E., Santora A., Barrett-Connor E., Black D.M. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J. Bone Miner. Res. 2013;28:1319-27
  8. Eastell R., Hannon R.A., Wenderoth D., Rodriguez-Moreno J., Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J. Clin. Endocrinol. Metab. 2011;96:3367-73.
  9. Leslie W., Lix L., Johansson H., Oden A., McCloskey E., Kanis J. Does osteoporosis therapy invalidate FRAX for fracture prediction? J. Bone Miner. Res. 2012;27:1243-51.
  10. Ringe J.D., Schacht E. Natürliches Vitamin D oder alfacalcidol als folgebehandlung langjahriger bisphosphonat-therapie bei postmenopausaler osteoporose. Osteology. 2012;21:83-7.
  11. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., Peacock M., Miller P.D., Lederman S.N., Chesnut C.H., Lain D., Kivitz A.J., Holloway D.L., Zhang C., Peterson M.C., Bekker P.J. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2006;354:821-31.
  12. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., Man H.S., San Martin J., Bone H.G. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res. 2010;25(1):72-81.
  13. Bone H.G., Brandi M.L., Brown J.P., Chapurlat R., Cummings S.R., Czerwinski E., Fahrleitner-Pammer A., Kendler D.L., Lippuner K., Reginster J-Y., Roux C., Vittinghoff E., Daizadeh N.S., Wang A., Dakin P., Wagman R.B., Papapoulos S. Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the FREEDOM Extension Trial. J. Bone Miner. Res. 2015;30 (Suppl. 1):S471.
  14. Ferrari S., Adami S., Brown J. P., Cosman F., Czerwinski E., de Gregdrio L. H., Malouf J., Reginster J.-Y., Daizadeh N.S., Wang A., Wagman R.B, Lewiecki E.M. Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of denosumab treatment. Osteoporos. Int. 2016;27 (Suppl 1):S39-S62.
  15. McClung M.R. Cancel the denosumab holiday. Osteoporos. Int. 2016;27(5):1677-82.
  16. Freemantle N., Satram-Hoang S., Tang E.T., Kaur P., Macarios D., Siddhanti S., Borenstein J., Kendler D.L.; DAPS Investigators. Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos. Int. 2012;23(1):317-26.
  17. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Mautalen C., Reginster J.Y., Stepan J.J., Myers S.L., Mitlak B.H. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 2004;164(9):2024-30.
  18. Торопцова Н.В. Вторичная профилактика остеопороза и остеопоротических переломов в реальной клинической практике и возможности ее повышения с помощью стронция ранелата. Современная ревматология. 2012;6(1):61-5. [Toroptsova N.V. Secondary prevention of osteoporosis and osteoporotic fractures in clinical practice and possibility of its improvement with the help of strontium ranelate. Modern rheumatology. 2012;6(1):61-5 (in Russ.)]
  19. Лесняк О.М., Никитинская О.А., Торопцова Н.В., Белая Ж.Е., Белова К.Ю., Бордакова Е.В., Гильманов А.Ж., Гуркина Е.Ю., Дорофейков В.В., Ершова О.Б., Зазерская И.Е., Зоткин Е.Г., Каронова Т.Л., Марченкова Л.А., Назарова А.В., Пигарова Е.А., Рожинская Л.Я., Сафонова Ю.А., Скрипникова И.А., Ширинян Л.В., Юренева С.В., Якушевская О.В. Профилактика, диагностика и лечение дефицита витамина D и кальция у взрослого населения России и пациентов с остеопорозом (по материалам подготовленных клинических рекомендаций). Научно-практическая ревматология. 2015;53(4):403-8. [Lesnyak O.M., Nikitinskaya O.A., Toroptsova N.V., Belaya Zh.Ye., Belova K.Yu., Bordakova Ye.V., Gil'manov A.Zh., Gurkina Ye.Yu., Dorofeikov V.V., Yershova O.B., Zazerskaya I.Ye., Zotkin Ye.G., Karanova T.L. Marchenkova L.A., Nazarova A.V., Pigarova Ye.A., Rozhinskaya L.Ya., Safonova Yu.A., Skripnikova I.A., Shirinyan L.V., Yureneva S.V., Yakushevskaya O.V. Prevention, diagnosis and treatment of vitamin D and calcium deficiency in the adult population and patients with osteoporosis (based on materials prepared by the clinical guidelines). Scientific-practical rheumatology. 2015;53(4):403-8 (in Russ.)]

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies